Related Experiment Videos
Reserpine does not prevent 3,4-methylenedioxymethamphetamine-induced neurotoxicity in the rat
C R Hekmatpanah1, D J McKenna, S J Peroutka
1Department of Neurology, Stanford University Medical School, CA 94305.
Neuroscience Letters
|September 25, 1989
Summary
3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity to serotonin (5-HT) nerve terminals is independent of dopamine (DA) or 5-HT stores. MDMA caused significant 5-HT terminal loss regardless of reserpine pre-treatment depleting monoamine stores.
Area of Science:
- Neuroscience
- Pharmacology
- Toxicology
Background:
- 3,4-Methylenedioxymethamphetamine (MDMA) is recognized as a neurotoxin targeting 5-hydroxytryptamine (5-HT) nerve terminals.
- Emerging research suggests that endogenous dopamine (DA) and/or 5-HT may play a role in mediating MDMA-induced neurotoxicity.
Purpose of the Study:
- To investigate whether endogenous dopamine (DA) or serotonin (5-HT) stores are necessary for MDMA-induced neurotoxicity.
- To determine if MDMA's neurotoxic effects on 5-HT terminals are dependent on the presence of DA or 5-HT.
Main Methods:
- Rats were pre-treated with reserpine to deplete central monoamine stores.
- Subsequent administration of MDMA (30 mg/kg) was performed.
- The density of 5-HT nerve terminals was quantified using [3H]paroxetine labeling.
Main Results:
- MDMA administration resulted in significant decreases in 5-HT nerve terminal density.
- This decrease was observed both in rats pre-treated with reserpine (51 +/- 8% reduction) and those without (43 +/- 20% reduction).
- The extent of 5-HT terminal loss was statistically similar between the two groups.
Conclusions:
- The neurotoxic degeneration of 5-HT nerve terminals induced by MDMA is independent of the presence of endogenous dopamine or serotonin.
- MDMA's toxicity to serotonin pathways does not rely on the availability of these monoamines within the central nervous system.